EFFECTS OF PSILOCYBIN IN TERMINAL CANCER PATIENTS WITH ANXIETY

裸盖菇素对晚期癌症患者焦虑的影响

• 批准号: 7952224
• 负责人: CHARLES GROB
• 金额: $ 0.74万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952224
• 关键词: Adult; Anxiety; Anxiety Disorders; Cancer Patient; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Crossover Design; Double-Blind Method; Funding; Grant; Hallucinogens; Individual; Informed Consent; Institution; Investigation; Learning; Life; Malignant Neoplasms; Measures; Nicotinic Acids; Nurses; Pain; Pharmaceutical Preparations; Placebos; Principal Investigator; Quality of life; Randomized; Research; Research Personnel; Resources; Source; Symptoms; United States National Institutes of Health; depression; improved; placebo controlled study; psychologic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a clinical study focused on management of physical and psychological symptoms to enhance the quality of life remaining for individuals who are nearing the end of their lives. The specific aim is to learn whether the hallucinogen, psilocybin, might be effective in reducing anxiety, depression and physical pain, and improving the quality of life in terminal cancer patients. 12 adult subjects with cancer with projected survival up to one year and anxiety disorder will be screened and given informed consent. This pilot investigation is a double-blind, placebo-controlled study with a crossover design. All subjects will receive 0.2 mg/kg of psilocybin during one treatment session and an active placebo, 250 mg of niacin, during a second session six weeks later, in a randomized sequence. The principal investigator and a master's level psychoterapist or nurse will remain with the subject until the effects of the drug have subsided. Efficacy will be evaluated by a variety of pre- and post-measures examining anxiety, depression, pain and quality of life.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项临床研究，重点是管理身体和心理症状，以提高生命接近尾声的人的生活质量。具体目的是了解迷幻剂裸盖菇素是否能有效地减轻晚期癌症患者的焦虑、抑郁和身体疼痛，并提高他们的生活质量。12名患有癌症和焦虑症的成年受试者将接受筛查，并给予知情同意。这项先导性研究是一项交叉设计的双盲、安慰剂对照研究。所有受试者将在一个疗程中接受0.2 mg/kg的裸盖菇素治疗，并在六周后的第二个疗程中随机接受250 mg烟酸的活性安慰剂。首席调查员和硕士级别的精神科医生或护士将留在受试者身边，直到药物的影响消退。疗效将通过各种前后措施进行评估，检查焦虑、抑郁、疼痛和生活质量。